| ORIGINAL ARTICLE |
|
| Year : 2023 | Volume
: 13
| Issue : 1 | Page : 43-48 |
|
|
Conjunctival inflammation and dry eye symptoms at day 100 post-transplantation do not predict risk for chronic graft-versus-host disease
Ankit M Shah1, Anat Galor2, Karla Mones3, Pepita Jean3, Krishna V Komanduri4, Trent P Wang3
1 University of Miami Miller School of Medicine, Miami, FL, USA
2 Bascom Palmer Eye Institute; Miami Veterans Affairs Medical Center, Miami, FL, USA
3 Division of Transplantation and Cellular Therapy, Sylvester Comprehensive Cancer Center, Adult Stem Cell Transplant Program, University of Miami Hospital and Clinics, Miami, FL, USA
4 Division of Hematology/Oncology, University of California San Francisco, Miami, FL, USA
Correspondence Address:
Dr. Trent P Wang
1411 NW 12th Ave, Suite 231, Miami, FL 33136
USA
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/tjo.TJO-D-22-00103
|
|
|
PURPOSE: Chronic graft-versus-host disease (cGVHD) is a significant cause of morbidity and mortality among patients after allogeneic hematopoietic stem cell transplant (HCT). The objective of our study was to determine if early assessment of matrix metalloproteinase-9 (MMP-9) and dry eye (DE) symptoms (via the DE Questionnaire-5 [DEQ-5]) had prognostic utility for the development of cGVHD and/or severe DE symptoms after HCT.
MATERIALS AND METHODS: This was a retrospective study of 25 individuals who underwent HCT and had MMP-9 (InflammaDry) and DEQ-5 performed on day 100 post-HCT (D + 100). Patients also completed the DEQ-5 at 6, 9, and 12 months post-HCT. The development of cGVHD was determined by chart review.
RESULTS: Overall, 28% of patients developed cGVHD over a median follow-up of 229 days. At D + 100, 32% of patients had a positive MMP-9 in at least one eye and 20% had a DEQ-5 ≥6. However, neither the presence of a positive MMP-9 nor a DEQ-5 score ≥6 at D + 100 predicted the development of cGVHD (MMP-9: hazard ratio [HR]: 1.53, 95% confidence interval [CI]: 0.34-6.85, P = 0.58; DEQ-5 ≥6: HR: 1.00, 95% CI: 0.12-8.32, P = 1.00). In addition, neither of these measures predicted the development of severe DE symptoms (DEQ-5 ≥12) over time (MMP-9: HR: 1.77, 95% CI: 0.24-12.89, P = 0.58; DEQ-5 >6: HR: 0.03, 95% CI: 0.00-889.93, P = 0.49).
CONCLUSION: Within our small cohort, DEQ-5 and MMP-9 assessment at D + 100 did not predict the development of cGVHD or severe DE symptoms.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
